Literature DB >> 15571797

Genome signatures of colon carcinoma cell lines.

Kristine Kleivi1, Manuel R Teixeira, Mette Eknaes, Chieu B Diep, Kjetill S Jakobsen, Richard Hamelin, Ragnhild A Lothe.   

Abstract

In cancer biology, cell lines are often used instead of primary tumors because of their widespread availability and close reflection of the in vivo state. Cancer is a genetic disease, commonly caused by small- and large-scale DNA rearrangements. Therefore, it is essential to know the genomic profiles of tumor cell lines to enable their correct and efficient use as experimental tools. Here, we present a comprehensive study of the genomic profiles of 20 colon cancer cell lines combining conventional karyotyping (G-banding), comparative genomic hybridization (CGH), and multicolor fluorescence in situ hybridization (M-FISH). Major differences between the microsatellite instability (MSI) and chromosome instability (CIN) cell lines are shown; the CIN cell lines exhibited complex karyotypes involving many chromosomes (mean: 8.5 copy number changes), whereas the MSI cell lines showed considerably fewer aberrations (mean: 2.6). The 3 techniques complement each other to provide a detailed picture of the numerical and structural chromosomal changes that characterize cancer cells. Therefore, 7 of the cell lines (Colo320, EB, Fri, IS2, IS3, SW480, and V9P) are here completely karyotyped for the first time and, among these, 5 have not previously been cytogenetically described. By hierarchical cluster analysis, we show that the cell lines are representative models for primary carcinomas at the genome level. We also present the genomic profiles of an experimental model for tumor progression, including 3 cell lines (IS1, IS2, and IS3) established from a primary carcinoma, its corresponding liver- and peritoneal metastasis from the same patient. To address the question of clonality, we compared the genome of 3 common cell lines grown in 2 laboratories. Finally, we compared all our results with previously published CGH data and karyotypes of colorectal cell lines. In conclusion, the large variation in genetic complexity of the cell lines highlights the importance of a comprehensive reference of genomic profiles for investigators engaged in functional studies using these research tools.

Entities:  

Mesh:

Year:  2004        PMID: 15571797     DOI: 10.1016/j.cancergencyto.2004.03.014

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  24 in total

1.  CD133 expression is not selective for tumor-initiating or radioresistant cell populations in the CRC cell line HCT-116.

Authors:  Claudia Dittfeld; Antje Dietrich; Susann Peickert; Sandra Hering; Michael Baumann; Marian Grade; Thomas Ried; Leoni A Kunz-Schughart
Journal:  Radiother Oncol       Date:  2010-03       Impact factor: 6.280

2.  Comparison of Sanger sequencing, pyrosequencing, and melting curve analysis for the detection of KRAS mutations: diagnostic and clinical implications.

Authors:  Athanasios C Tsiatis; Alexis Norris-Kirby; Roy G Rich; Michael J Hafez; Christopher D Gocke; James R Eshleman; Kathleen M Murphy
Journal:  J Mol Diagn       Date:  2010-04-29       Impact factor: 5.568

3.  Molecular inversion probe analysis of gene copy alterations reveals distinct categories of colorectal carcinoma.

Authors:  Hanlee Ji; Jochen Kumm; Michael Zhang; Kyle Farnam; Keyan Salari; Malek Faham; James M Ford; Ronald W Davis
Journal:  Cancer Res       Date:  2006-08-15       Impact factor: 12.701

4.  Irinotecan and DNA-PKcs inhibitors synergize in killing of colon cancer cells.

Authors:  David Davidson; Yannick Coulombe; Veronica L Martinez-Marignac; Lilian Amrein; Jeremy Grenier; Keira Hodkinson; Jean-Yves Masson; Raquel Aloyz; Lawrence Panasci
Journal:  Invest New Drugs       Date:  2011-01-11       Impact factor: 3.850

5.  Common fusion transcripts identified in colorectal cancer cell lines by high-throughput RNA sequencing.

Authors:  Torfinn Nome; Gard Os Thomassen; Jarle Bruun; Terje Ahlquist; Anne C Bakken; Andreas M Hoff; Torleiv Rognum; Arild Nesbakken; Susanne Lorenz; Jinchang Sun; João Diogo Barros-Silva; Guro E Lind; Ola Myklebost; Manuel R Teixeira; Leonardo A Meza-Zepeda; Ragnhild A Lothe; Rolf I Skotheim
Journal:  Transl Oncol       Date:  2013-10-01       Impact factor: 4.243

6.  Topoisomerase IIalpha binding domains of adenomatous polyposis coli influence cell cycle progression and aneuploidy.

Authors:  Yang Wang; Robert J Coffey; Neil Osheroff; Kristi L Neufeld
Journal:  PLoS One       Date:  2010-04-02       Impact factor: 3.240

7.  Integrative genomics reveals mechanisms of copy number alterations responsible for transcriptional deregulation in colorectal cancer.

Authors:  Jordi Camps; Quang Tri Nguyen; Hesed M Padilla-Nash; Turid Knutsen; Nicole E McNeil; Danny Wangsa; Amanda B Hummon; Marian Grade; Thomas Ried; Michael J Difilippantonio
Journal:  Genes Chromosomes Cancer       Date:  2009-11       Impact factor: 5.006

8.  Definitive molecular cytogenetic characterization of 15 colorectal cancer cell lines.

Authors:  Turid Knutsen; Hesed M Padilla-Nash; Danny Wangsa; Linda Barenboim-Stapleton; Jordi Camps; Nicole McNeil; Michael J Difilippantonio; Thomas Ried
Journal:  Genes Chromosomes Cancer       Date:  2010-03       Impact factor: 5.006

9.  Identification of an epigenetic biomarker panel with high sensitivity and specificity for colorectal cancer and adenomas.

Authors:  Guro E Lind; Stine A Danielsen; Terje Ahlquist; Marianne A Merok; Kim Andresen; Rolf I Skotheim; Merete Hektoen; Torleiv O Rognum; Gunn I Meling; Geir Hoff; Michael Bretthauer; Espen Thiis-Evensen; Arild Nesbakken; Ragnhild A Lothe
Journal:  Mol Cancer       Date:  2011-07-21       Impact factor: 27.401

10.  Breast cancer cell lines carry cell line-specific genomic alterations that are distinct from aberrations in breast cancer tissues: comparison of the CGH profiles between cancer cell lines and primary cancer tissues.

Authors:  Katumi Tsuji; Shigeto Kawauchi; Soichiro Saito; Tomoko Furuya; Kenzo Ikemoto; Motonao Nakao; Shigeru Yamamoto; Masaaki Oka; Takashi Hirano; Kohsuke Sasaki
Journal:  BMC Cancer       Date:  2010-01-14       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.